49713-58-8 Usage
General Description
4-chloroquinoline-7-carboxylic acid is a chemical compound with the molecular formula C10H6ClNO2. 4-chloroquinoline-7-carboxylic acid is a derivative of quinoline and is primarily used as an intermediate or building block in the synthesis of pharmaceuticals and agrochemicals. It possesses a chloro substituent at the 4th position and a carboxylic acid group at the 7th position of the quinoline ring. Its structure and properties make it a valuable tool in the development of drugs and other biologically active compounds. Additionally, 4-chloroquinoline-7-carboxylic acid has been studied for its potential antimicrobial and antitumor activities, making it a target for further research and development in the fields of medicine and agriculture.
Check Digit Verification of cas no
The CAS Registry Mumber 49713-58-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,9,7,1 and 3 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 49713-58:
(7*4)+(6*9)+(5*7)+(4*1)+(3*3)+(2*5)+(1*8)=148
148 % 10 = 8
So 49713-58-8 is a valid CAS Registry Number.
InChI:InChI=1/C10H6ClNO2/c11-8-3-4-12-9-5-6(10(13)14)1-2-7(8)9/h1-5H,(H,13,14)
49713-58-8Relevant articles and documents
BICYCLIC COMPOUNDS
-
Paragraph 00248, (2020/06/01)
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF
-
Paragraph 00320, (2016/08/17)
This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R4, Rq, o, RA, W and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease.
NOVEL QUINOLINE DERIVATIVES
-
Page/Page column 59-60, (2008/06/13)
The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
